Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to predict drug failure in rare blood cancer

NCT ID NCT05853458

Terminated Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first time. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA

Contacts and locations

Locations

  • Novartis Investigative Site

    Heidelberg, Baden-Wurttemberg, 69115, Germany

  • Novartis Investigative Site

    Kronach, Bavaria, 96317, Germany

  • Novartis Investigative Site

    Straubing, Bavaria, 94315, Germany

  • Novartis Investigative Site

    Langen, Hesse, 63225, Germany

  • Novartis Investigative Site

    Lingen, Lower Saxony, 49808, Germany

  • Novartis Investigative Site

    Aachen, North Rhine-Westphalia, 52064, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50674, Germany

  • Novartis Investigative Site

    Dortmund, North Rhine-Westphalia, 44309, Germany

  • Novartis Investigative Site

    Velbert, North Rhine-Westphalia, 42551, Germany

  • Novartis Investigative Site

    Saarbrücken, Saarland, 66113, Germany

  • Novartis Investigative Site

    Merseburg, Saxony-Anhalt, 06217, Germany

  • Novartis Investigative Site

    Berlin, 10407, Germany

  • Novartis Investigative Site

    Donauwörth, 86609, Germany

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Erding, 85435, Germany

  • Novartis Investigative Site

    Gütersloh, 33332, Germany

  • Novartis Investigative Site

    Hanover, 30161, Germany

  • Novartis Investigative Site

    Kiel, 24105, Germany

  • Novartis Investigative Site

    Mutlangen, 73557, Germany

  • Novartis Investigative Site

    Naunhof, 04683, Germany

  • Novartis Investigative Site

    Würselen, 52146, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.